EXHIBIT 4.4


 


DESCRIPTION OF THE CAPITAL STOCK


 


TFF Pharmaceuticals,
Inc. (“Company”, “we”, “us” and “our”) has one class of securities registered under
Section 12 of the Securities Exchange Act of 1934, as amended, namely our common stock, par value $0.001 per share.


 


The following is a
summary of the rights of our common and of certain provisions of our Second Amended and Restated Certificate of Incorporation (“Certificate
of Incorporation”) and Amended and Restated Bylaws (“Bylaws”). For more detailed information, please see our
Certificate of Incorporation and Bylaws, which are incorporated by reference as exhibits to the Annual Report on Form 10-K to which
this description is an exhibit.


 


Common Stock


 


Our Certificate of Incorporation
authorizes us to issue up to 45,000,000 shares of common stock, $0.001 par value per share. As of March [●], 2021, we
had 23,063,491 shares of common stock outstanding, held by [●] stockholders of record.


 


Holders of shares of
common stock are entitled to one vote per share on all matters to be voted upon by the stockholders generally. Stockholders are
entitled to receive such dividends as may be declared from time to time by the Board out of funds legally available therefore,
and in the event of liquidation, dissolution or winding up of the company to share ratably in all assets remaining after payment
of liabilities. The holders of shares of common stock have no preemptive, conversion, subscription rights or cumulative voting
rights.


 


Preferred Stock


 


Prior to our initial
public offering in October 2019, our Certificate of Incorporation authorized us to issue up to 10,000,000 shares of preferred stock,
all of which was designated as Series A preferred stock and there were 8,930,000 shares of Series A preferred stock issued
and outstanding immediately prior to our initial public offering. Pursuant to our Certificate of Incorporation, all outstanding
shares of Series A preferred stock automatically converted to common stock at the close of our initial public offering and thereafter
we were no longer authorized to issue any preferred stock.


 


Dividends


 


We have never paid cash
dividends on our common stock and we do not anticipate the payment of cash dividends on our common stock in the foreseeable future.


 


Anti-Takeover Effects of Certain Provisions of Delaware Law


 


We are subject to the
provisions of Section 203 of the Delaware General Corporation Law, or DGCL, an anti-takeover law. In general, Section 203 prohibits
a publicly held Delaware corporation from engaging in a “business combination’’ with an “interested stockholder’’
for a period of three years after the date of the transaction in which such stockholder became an interested stockholder, unless
the business combination is approved in a prescribed manner. For purposes of Section 203, a “business combination’’
includes a merger, asset sale or other transaction resulting in a financial benefit to the interested stockholder, and an “interested
stockholder’’ is a stockholder who, together with affiliates and associates, owns, or within three years prior, did
own, 15% or more of the voting stock.


 


Transfer Agent and Registrar


 


The transfer agent and registrar for our
common stock is Philadelphia Stock Transfer, 2320 Haverford Road, Suite 230, Ardmore, PA 19003.